DealFlow OS
Get started free
Deal Structure Guide · Drug Testing Services

How Drug Testing Businesses Are Bought and Sold: Deal Structure Guide

From SBA-financed asset purchases to PE-backed equity rollovers, learn how to structure a drug testing services transaction that protects both sides and closes at the right price.

Drug testing services businesses in the $1M–$5M revenue range trade at 3.5x–6x EBITDA, with valuation driven heavily by the durability of employer contracts, regulatory compliance history, and the degree to which revenue is truly recurring versus tied to the owner's personal relationships. Because a meaningful portion of top-line revenue typically represents pass-through lab and MRO charges, buyers and sellers must agree early on how to isolate and present true service margin — a distinction that directly shapes what financing structure is feasible. Most transactions in this space are structured as asset purchases with SBA 7(a) debt as the primary financing vehicle, often layered with a seller note and an earnout tied to client retention. Strategic acquirers and PE-backed roll-up platforms may propose equity rollover structures to retain the seller's regulatory expertise and client relationships during integration. Understanding which structure fits your situation — and how each affects price, risk, and post-close obligations — is essential before entering any letter of intent.

Find Drug Testing Services Businesses For Sale

SBA 7(a) Asset Purchase with Seller Note

The most common structure for independent buyers acquiring a drug testing business. The buyer finances 75–85% of the purchase price through an SBA 7(a) loan, contributes 10–15% equity, and the seller carries a subordinated note for the remaining 5–10%. The deal is structured as an asset purchase, with consideration allocated across goodwill, client lists, collector equipment, and non-compete agreements. The seller note is typically held for 24 months and may be partially at-risk if key accounts churn within the holdback period.

SBA loan: 75–80%, buyer equity: 10–15%, seller note: 5–10%

Pros

  • Maximizes buyer leverage with favorable SBA loan terms up to 10 years, keeping debt service manageable on a business with predictable DOT and employer contract cash flows
  • Seller note aligns seller incentives with a clean transition, particularly important when owner manages key corporate accounts or performs MRO reviews personally
  • Asset purchase structure allows buyer to step up basis in goodwill and client lists, creating depreciation and amortization tax benefits post-close

Cons

  • SBA lenders will scrutinize pass-through lab revenue and may underwrite to a lower adjusted EBITDA than seller expects, creating a valuation gap at the term sheet stage
  • Seller must accept subordination of their note behind SBA debt, limiting recourse if the buyer underperforms post-close
  • Due diligence timelines for SBA transactions are longer, typically 60–90 days, requiring the seller to maintain full business operations and client relationships during an extended process

Best for: First-time entrepreneurial buyers with HR, compliance, or occupational health backgrounds acquiring an established regional drug testing network using SBA financing as the primary capital source.

Asset Purchase with Earnout Tied to Client Retention

The purchase price is split between a cash payment at close and an earnout paid over 12–36 months, contingent on retaining specific employer accounts or maintaining revenue thresholds above an agreed baseline. This structure is particularly common in drug testing deals where the seller owns relationships with large transportation fleets, construction contractors, or government testing programs that could churn if the owner departs abruptly. The earnout is typically calculated as a percentage of collections revenue or EBITDA from a defined client cohort.

Cash at close: 65–80%, earnout: 20–35% paid over 12–36 months based on client retention or revenue milestones

Pros

  • Bridges the valuation gap when buyers are uncertain about the durability of employer contracts that are month-to-month or relationship-dependent rather than governed by long-term agreements
  • Motivates seller to actively support transition and client introductions during the earnout period, reducing the risk of account loss that is common in owner-operated drug testing businesses
  • Allows the total deal price to reflect a higher valuation than the buyer would accept on a fully upfront cash basis, improving seller satisfaction while protecting buyer downside

Cons

  • Earnout disputes are common if contract language around revenue measurement, excluded pass-through charges, or client attribution is not precisely defined before close
  • Seller is exposed to operational decisions made by the new owner — such as changes to collection site hours, pricing, or technology — that could reduce earnout achievement independent of their own transition efforts
  • Buyers may face integration delays if the seller withholds full operational handover until earnout conditions are confirmed, creating ambiguity in day-to-day management authority

Best for: Transactions where owner dependency is high — particularly when the seller personally manages MRO reviews, DOT consortium accounts, or corporate HR relationships that represent a concentrated portion of testing volume.

Equity Rollover under PE-Backed Roll-Up Platform

A private equity-backed occupational health or background screening platform acquires a controlling interest in the drug testing business, with the seller retaining a 10–20% minority equity stake in the combined entity. The seller receives a partial liquidity event at close and participates in the upside of the platform's future growth and eventual exit. This structure is increasingly common as national roll-up platforms target regional drug testing networks with strong DOT consortium management, mobile collection fleets, or dense collection site coverage in key metropolitan markets.

Cash at close: 80–90% of agreed enterprise value, equity rollover: 10–20% retained as minority stake in acquiring platform

Pros

  • Seller participates in a second liquidity event when the platform sells, potentially generating a total return that exceeds what a standalone sale would have produced
  • PE platform brings operational infrastructure — technology, compliance systems, centralized MRO, and national lab contracts — that can accelerate revenue growth and margin improvement for the acquired business
  • Retaining a minority stake signals seller confidence in the business and often results in a higher upfront valuation multiple from the acquiring platform than a full cash-out structure would command

Cons

  • Seller gives up control and must align with platform operating standards, which may include changes to collection site procedures, technology systems, lab vendor relationships, and pricing models
  • Minority equity value depends entirely on the platform's future performance and exit timeline, which can be 3–7 years away and subject to market conditions outside the seller's control
  • Rollover equity structures carry complexity around governance rights, drag-along provisions, and distribution waterfalls that require experienced legal counsel to negotiate fairly

Best for: Sellers with high-quality DOT consortium management operations, proprietary collection infrastructure, or dense employer contract bases in transportation or construction who want to participate in platform-level value creation rather than a full exit.

Sample Deal Structures

SBA-Financed Acquisition of Regional Employer Drug Testing Network

$2,100,000

SBA 7(a) loan: $1,575,000 (75%); buyer equity injection: $315,000 (15%); seller note: $210,000 (10%)

10-year SBA loan at prime plus 2.75%; seller note at 6% interest over 24 months, subordinated to SBA debt; 12-month non-compete agreement; 90-day transition period with seller available for account introductions and collector certification handover; purchase price allocated as goodwill $1,400,000, client list $500,000, collector equipment $150,000, non-compete $50,000

Asset Purchase with Earnout for Owner-Dependent DOT Consortium Business

$3,400,000 total (base $2,550,000 plus earnout up to $850,000)

Cash at close: $2,550,000 (75%); earnout: up to $850,000 (25%) paid over 24 months based on retention of the top 15 employer accounts representing 60% of annual collection revenue

Earnout measured quarterly against baseline revenue from defined account cohort; seller receives 50% of earnout if retention exceeds 80% of baseline revenue and 100% if retention exceeds 95%; seller remains as a paid transition consultant at $8,500 per month for 18 months; 24-month non-compete in applicable MSAs; chain-of-custody software and LIMS license transferred at close

PE Roll-Up Platform Acquisition with Equity Rollover

$5,200,000 enterprise value (4.8x EBITDA on $1,080,000 adjusted EBITDA)

Cash to seller at close: $4,420,000 (85%); equity rollover: $780,000 (15%) retained as minority stake in acquiring occupational health platform

Rollover equity converted to platform units at same implied valuation; standard tag-along and drag-along rights with 5-year target hold; seller transitions to regional director role at $120,000 annual salary for 3 years; lab and MRO vendor contracts assigned to platform; seller receives pro-rata distribution at platform exit based on unit ownership; 3-year non-solicitation of platform clients post-employment

Negotiation Tips for Drug Testing Services Deals

  • 1Separate pass-through lab and MRO charges from true collection service revenue before any valuation discussion begins — buyers will underwrite to net revenue and adjusted EBITDA, not gross billings, and sellers who conflate the two will face a painful repricing late in the process
  • 2If an earnout is proposed, insist on defining the measurement metric as gross collection revenue from a named account list rather than net income or EBITDA, which the buyer can influence through post-close cost decisions that are outside the seller's control
  • 3Ensure all DOT collector certifications, SAMHSA-certified lab agreements, and state occupational health licenses are confirmed transferable or re-issuable before signing a letter of intent — a compliance gap discovered in due diligence can delay close by 60–90 days or trigger a price reduction
  • 4Negotiate the transition period length and compensation separately from the purchase price — a well-structured 12–18 month consulting arrangement with defined milestones gives both parties clarity and reduces earnout disputes tied to owner dependency
  • 5Request a representation and warranty provision requiring the seller to notify the buyer of any DOT audit findings, HIPAA complaints, or client non-renewal notices during the period between LOI signing and close, protecting the buyer from adverse developments that emerge during due diligence
  • 6For PE roll-up transactions, have legal counsel negotiate governance protections for rollover equity before close, including a minimum distribution threshold, approved sale process rights, and protection against dilutive capital raises that would reduce the seller's effective ownership percentage below the agreed rollover amount

Find Drug Testing Services Businesses For Sale

Pre-screened targets ready for your deal structure — free to join.

Get Deal Flow

Frequently Asked Questions

Why do most drug testing business acquisitions use an asset purchase rather than a stock purchase?

Asset purchases allow buyers to avoid inheriting unknown liabilities — including prior DOT audit findings, HIPAA violations, or undisclosed regulatory citations — that would transfer automatically in a stock deal. They also allow the buyer to allocate purchase price to goodwill, client lists, and equipment for favorable tax treatment. Sellers may push back on asset purchase structures due to less favorable capital gains treatment on certain allocated assets, so the final structure is often a negotiated compromise with purchase price allocation agreed as part of the LOI.

How is the seller note typically structured in a drug testing business acquisition?

In most SBA-financed drug testing deals, the seller note represents 5–10% of the purchase price, carries a 5–7% interest rate, and is held for 24 months following close. SBA lenders require the seller note to be fully subordinated to SBA debt, meaning the seller cannot receive principal payments until the SBA loan is in good standing. The seller note effectively functions as a performance guarantee — if key employer accounts churn or compliance issues surface post-close, the buyer has leverage to negotiate a reduction in the note balance before final payment.

How should a seller handle the valuation challenge created by pass-through lab revenue?

Sellers should prepare a revenue bridge that clearly separates direct collection fees, DOT consortium management fees, and MRO service revenue — which carry meaningful margins — from pass-through laboratory charges, which flow through the income statement with little or no markup. Buyers and their lenders will rebuild the P&L using only margin-generating revenue streams, so presenting clean adjusted financials upfront prevents a valuation gap from emerging during due diligence. Working with a healthcare-focused M&A advisor to normalize EBITDA before going to market is strongly recommended.

What triggers an earnout in a drug testing acquisition and how are disputes avoided?

Earnouts in drug testing transactions are most commonly triggered by failure to retain key employer accounts or collections revenue falling below a defined threshold during the earnout period. Disputes are avoided by drafting the earnout with a specific named account list, a precise revenue measurement methodology that excludes pass-through lab charges, quarterly measurement periods with third-party accountant verification, and explicit provisions protecting the seller from buyer-initiated pricing changes or service disruptions that reduce client revenue outside the seller's control. Both parties should have legal counsel review the earnout mechanics before LOI execution.

What is an equity rollover and when should a drug testing business seller consider it?

An equity rollover allows the seller to convert a portion of their sale proceeds — typically 10–20% — into ownership units of the acquiring platform rather than receiving full cash at close. This structure makes sense when the seller believes the acquiring platform will grow significantly through additional acquisitions and an eventual sale at a higher multiple than a standalone exit would achieve. It is most appropriate for sellers with high-quality DOT consortium operations, strong employer contract bases, or proprietary collection infrastructure that adds strategic value to a roll-up platform. Sellers should independently assess the platform's financial health, management team, and exit track record before accepting rollover equity in lieu of cash.

Does SBA financing work for drug testing business acquisitions?

Yes, drug testing services businesses are generally SBA-eligible as they are not passive investment vehicles and typically operate as active service businesses with employees and physical collection infrastructure. SBA 7(a) loans are the most common financing vehicle for independent buyers acquiring drug testing companies in the $1M–$5M revenue range. Lenders will underwrite to adjusted EBITDA after removing pass-through lab charges, owner compensation add-backs, and non-recurring expenses. A clean three-year earnings history, current DOT certifications, diversified employer client base, and no pending regulatory actions are the key factors that determine SBA lender appetite and loan sizing.

More Drug Testing Services Guides

Acquire a Drug Testing Services Business →Valuation Guide →SBA Loan Guide →LOI Template →Due Diligence →

More Deal Structure Guides

Dry Cleaning & Alterations →Drywall Contractor →E-commerce →E-commerce Agency →Electrical Contracting →Electrical Contracting →Electrical Supply Distributor →Email Marketing Agency →Browse all deal structure guides →

Start Finding Drug Testing Services Deals Today — Free to Join

Find the right target, structure the deal, and close with confidence.

Create your free account

No credit card required

For Buyers

For Sellers

Free Tools

Platform

DealFlow OS
© 2026 DealFlow OSPrivacy PolicyTerms of Service